Magnesium Oxide interactions
Full monograph for Magnesium OxideCheck it against another medicine
Medicines
234 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Gefitinib | Major | Absorption | Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib. According… | 5 sources — open the full entry |
| Selpercatinib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in… | 2 sources — open the full entry |
| Sotorasib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma. | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Absorption | INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its… | 2 sources — open the full entry |
| Alendronic acid | Moderate | Absorption | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to… | 9 sources — open the full entry |
| Alendronic Acid + Vitamin D3 | Moderate | Absorption · Synergy | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…2 documented mechanisms | 13 sources — open the full entry |
| Algae Calcium + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Aspirin | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Baloxavir Marboxil | Moderate | Absorption | Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed… | 3 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Absorption · Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 11 sources — open the full entry |
| Calcitriol | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium + Vitamin D3 + Multimineral | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium acetate + Magnesium carbonate | Moderate | Synergy | The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium… | 1 sources — open the full entry |
| Calcium Citrate + Calcitriol | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Calcium Phosphate [Milk source] + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Cefdinir | Moderate | Absorption | INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but… | 1 sources — open the full entry |
| Cefditoren | Moderate | Absorption | Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil. | 2 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Ceritinib | Moderate | Absorption | Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been… | 2 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Absorption | INTERVAL: Concomitant administration of antacids or kaolin may reduce the oral bioavailability of chloroquine. The proposed mechanism is adsorption of… | 9 sources — open the full entry |
| Cholecalciferol [Vitamin D3] | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 35 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Conventional Calcium + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Coral Calcium + Vitamin D3 | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Moderate | Absorption | Coadministration with an antacid may reduce the bioavailability of dabigatran following oral administration of dabigatran etexilate. | 1 sources — open the full entry |
| Dasatinib | Moderate | Absorption | INTERVAL: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, coadministration with antacids or agents with… | 4 sources — open the full entry |
| Deferiprone | Moderate | Absorption | INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use… | 1 sources — open the full entry |
| Delafloxacin | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
Conditions
Conditions in which Magnesium Oxide needs care, as documented in this source.
Kidney Diseases
MajorMagnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.
5 sources
- "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Slow-Mag (magnesium chloride)." Searle (2001):
- "Product Information. Magonate (magnesium gluconate)." Fleming and Company (2001):
- "Product Information. Losospan (magaldrate)." Whitehall-Robbins (2001):
Therapeutic duplication
Drug classes that overlap with Magnesium Oxide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Nu-mag
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Renacidin
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Suprep bowel prep kit
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Sutab
magnesium
The recommended maximum number of medicines in the 'magnesium' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'magnesium' category.
Example product in the source data (US market): Aluminum hydroxide/magnesium carbonate